I can totally understand what you say and can relate to you because I'm in several Biotech companies and it's like watching paint dry lol. Patients are the word on them. Had traded a couple of them for some nice gains in 2020 and 2021 but this year has been a total bore.
Ok bro have a nice weekend and I gave you a member mark so we can stay in touch
Ok bro have a nice weekend and I gave you a member mark so we can stay in touch
Recent ADXN News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/23/2026 10:05:05 AM
- Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026 • GlobeNewswire Inc. • 04/23/2026 05:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/21/2026 10:05:05 AM
- Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model • GlobeNewswire Inc. • 04/21/2026 05:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/25/2026 08:03:03 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/25/2026 08:02:26 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/25/2026 08:01:48 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/25/2026 08:01:11 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 03:06:22 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/03/2026 11:05:03 AM
- Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment • GlobeNewswire Inc. • 02/03/2026 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/07/2026 11:05:05 AM
- Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia • GlobeNewswire Inc. • 01/07/2026 06:00:00 AM
- Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co. • GlobeNewswire Inc. • 12/11/2025 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/10/2025 09:03:08 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/10/2025 09:01:19 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/04/2025 11:00:31 AM
- Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 12/04/2025 06:00:00 AM
- Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025 • GlobeNewswire Inc. • 12/01/2025 06:00:00 AM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 11/19/2025 09:00:45 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/29/2025 10:35:05 AM
- Addex Increases Issued Share Capital to Create Treasury Shares • GlobeNewswire Inc. • 10/29/2025 06:00:00 AM
- DAX, CAC, FTSE100, European Markets Show Mixed Performance Amid U.S. Shutdown Concerns • UK Market News • 09/30/2025 01:17:04 PM
